ArticleBMC cancer2021

Novel chemotherapeutic agent FX-9 activates NF-κB signaling and induces G1 phase arrest by activating CDKN1A in a human prostate cancer cell line.

F Weiner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.